Randomized Phase 3 Study Evaluating the Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Phase of Trial: Phase III
Latest Information Update: 21 Oct 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary) ; Gemcitabine; Romidepsin
- Indications Peripheral T-cell lymphoma
- Focus Therapeutic Use
- Acronyms ORACLE
- Sponsors Celgene Corporation
- 30 Jun 2019 Planned number of patients changed from 20 to 86.
- 19 Feb 2019 Planned number of patients changed from 86 to 20.
- 19 Feb 2019 Status changed from not yet recruiting to recruiting.